**The impact of emerging *Plasmodium knowlesi* on accurate diagnosis by light microscopy: a**

**systematic review and modelling analysis**

John H. Huber*, Margaret Elliott, Cristian Koepfli, T. Alex Perkins

Department of Biological Sciences and Eck Institute for Global Health, University of Notre

Dame, Notre Dame, IN, USA

Keywords: *Plasmodium knowlesi*; misdiagnosis; light microscopy; systematic review;

Word Count: 245 (Abstract); 2,660 (Main Text)

Figures: 4; Tables: 1; Supplementary Files: 1

Running Head: Misdiagnosis of malaria by microscopy

100 Galvin Life Sciences Center, Notre Dame, IN 46556; huber.j.h@wustl.edu

**ABSTRACT**

The five *Plasmodium* spp. that cause human malaria appear similar under light microscopy, which raises the possibility that misdiagnosis could routinely occur in clinical settings. Assessing the extent of misdiagnosis is of particular importance for monitoring *P. knowlesi*, which co-circulates with the other *Plasmodium* spp. We performed a systematic review and meta-analysis of studies comparing the performance of microscopy and PCR for diagnosing malaria in settings with co-circulation of the five *Plasmodium* spp. We assessed the extent to which co-circulation of *Plasmodium* parasites affects diagnostic outcomes. We fit a Bayesian hierarchical latent class model to estimate variation in microscopy sensitivity and specificity. Mean sensitivity of microscopy was low, yet highly variable across *Plasmodium* spp., ranging from 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum* and 40.3% (22.0 – 61.5%) for *P. vivax* to 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 – 22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale.* Observed PCR prevalence was positively correlated with estimated microscopic sensitivity and negatively correlated with estimated microscopic specificity, though the strength of the associations varied by species. Our analysis suggests that co-circulation of *Plasmodium* spp. undermines the accuracy of microscopy. Sensitivity was considerably lower for *P. knowlesi*, *P. malariae*, and *P. ovale*. The negative association between specificity and prevalence imply that less frequently encountered species may be misdiagnosed as more frequently encountered species. Together, these results suggest that the burden of *P. knowlesi*, *P. malariae*, and *P. ovale* may be underappreciated in a clinical setting.

100 Galvin Life Sciences Center, Notre Dame, IN 46556; huber.j.h@wustl.edu

## INTRODUCTION

*Plasmodium falciparum* and *Plasmodium vivax* are the predominant parasites responsible for human malaria worldwide, causing an estimated 193.9 million and 14.3 million clinical cases in 2017, respectively[1,2]. Given their contribution to the global burden of malaria, *P. falciparum* and *P. vivax* remain the primary focus of public health efforts aimed at achieving malaria elimination and eradication[3]. However, three additional *Plasmodium* species—*P. knowlesi*, *P. malariae*, and *P. ovale*—also cause clinical episodes of malaria, though their overall burden remains uncertain due in part to routine misdiagnosis in a clinical setting[4].

Diagnosis of clinical malaria is routinely performed using light microscopy (LM). In addition to challenges presented by low or submicroscopic parasite densities[5], accurate speciation of malaria parasites using LM depends upon identification of morphological features characteristic of the *Plasmodium* spp. causing the infection. However, morphological similarities across the five *Plasmodium* spp., such as the resemblance of early blood-stage *P. knowlesi* parasites to *P. falciparum* parasites and late blood-stage *P. knowlesi* parasites to *P. malariae* parasites[3,6], undermine species-level identification of *Plasmodium* infections[7].

In settings with co-circulation of the *Plasmodium* spp., routine misdiagnosis by light microscopy has consequences for clinical decision-making and malaria control. The choice of therapeutic is specific to the *Plasmodium* spp. causing the infection[8], so misdiagnosis may lead to ineffective treatment of blood-stage parasites for all *Plasmodium* spp. infections as well as ineffective or no treatment of liver-stage parasites for *P. vivax* and *P. ovale* infections. Additionally, misdiagnosis may present challenges for monitoring *Plasmodium* spp. transmission, particularly for the emerging zoonosis *P. knowlesi*. Currently, the extent of human-

to-human transmission of *P. knowlesi* is unknown[3,9], and misdiagnosis could cause transmission

clusters to appear smaller than their actual size, leading to an underestimate of transmission[10].

Consequently, measuring the extent of misdiagnosis by light microscopy is of importance

to public health, and past studies have directly compared the diagnostic performance of light

microscopy to polymerase chain reaction (PCR) in settings with co-circulation of *Plasmodium*

spp. parasites[7,11–22]. However, these studies varied in their criteria for enrollment and other study

design features, as well as in the epidemiological settings in which they were conducted. This

makes direct comparison of their estimates of diagnostic performance challenging.

To synthesize across these studies, we performed a systematic review and meta-analysis

of the diagnostic performance of light microscopy in settings with co-circulation of all five

*Plasmodium* spp. We identified studies that compared the diagnostic performance of light

microscopy to PCR and fit a hierarchical Bayesian latent class model to estimate study-level and

species-level sensitivities and specificities of light microscopy. Finally, to assess whether the

perceived prevalences of the five species might affect diagnostic outcomes of light microscopy,

we explored the relationship between the estimates of sensitivity and specificity that we obtained

and the observed PCR prevalences in each study.

**METHODS**

**Search Strategy and Selection Criteria**

In this systematic review and meta-analysis, JHH searched MEDLINE and Web of Science for

studies published in English before April 30th, 2020 that compared the diagnostic performance of

light microscopy (LM) and polymerase chain reaction (PCR) for *Plasmodium* spp. infections.

We identified studies using the following search strategy: (*Plasmodium* OR malaria) AND

*knowlesi* AND ((microscopy OR microscopic OR blood film OR thick film OR thin film) AND

(PCR or "polymerase chain reaction")).

Studies met the criteria for inclusion if they compared the performance of LM and PCR

on clinical samples collected in areas with endemic transmission of all five *Plasmodium* spp. that

naturally infect humans (i.e., *P. falciparum*, *P. vivax*, *P. knowlesi*, *P. malariae*, and *P. ovale*).

Furthermore, studies were only included if they used a PCR protocol that was capable of

amplifying DNA from all five *Plasmodium* spp. Prior to 2004, the public health burden of *P.*

*knowlesi* was underappreciated[6], so restricting our search to studies published between 2004 and

2021 ensured that the diagnostic outcomes were representative of the current clinical and

diagnostic landscape.

The data were extracted from each study that met the criteria for inclusion. Because the

data in each study was anonymized and reported in aggregate, ethical approvals were not

required according to a determination from the University of Notre Dame Institutional Review

Board that this study did not constitute human subjects research.

**Data Analysis**

*Overview*

To model the diagnostic performance of LM and PCR, we constructed a Bayesian hierarchical

latent class model of clinical diagnosis[23]. In this model, the probability $p_{ijkl}$ of obtaining LM

outcome $i \in \{1,0\}$ and PCR outcome $j \in \{1,0\}$ for *Plasmodium* spp. $k$ in study $l$ is

$$p_{ijkl} = \begin{cases} se_{LM}^{(k,l)} se_{PCR}^{(k,l)} \theta_k^{(l)} + \left(1 - sp_{LM}^{(k,l)}\right)\left(1 - sp_{PCR}^{(k,l)}\right)\left(1 - \theta_k^{(l)}\right), & i = 1, j = 1 \\ se_{LM}^{(k,l)}\left(1 - se_{PCR}^{(k,l)}\right)\theta_k^{(l)} + \left(1 - sp_{LM}^{(k,l)}\right)sp_{PCR}^{(k,l)}\left(1 - \theta_k^{(l)}\right), & i = 1, j = 0 \\ \left(1 - se_{LM}^{(k,l)}\right)se_{PCR}^{(k,l)}\theta_k^{(l)} + sp_{LM}^{(k,l)}\left(1 - sp_{PCR}^{(k,l)}\right)\left(1 - \theta_k^{(l)}\right), & i = 0, j = 0 \\ \left(1 - se_{LM}^{(k,l)}\right)\left(1 - se_{PCR}^{(k,l)}\right)\theta_k^{(l)} + sp_{LM}^{(k,l)} sp_{PCR}^{(k,l)}\left(1 - \theta_k^{(l)}\right), & i = 0, j = 0 \end{cases} \quad (1)$$

In eq. (1), $se_{LM}^{(k,l)}$ and $sp_{LM}^{(k,l)}$ are the sensitivity and specificity of LM for *Plasmodium* spp. $k$ in

study $l$, $se_{PCR}^{(k,l)}$ and $sp_{PCR}^{(k,l)}$ are the sensitivity and specificity of PCR for *Plasmodium* spp. $k$ in

study $l$, and $\theta_k^{(l)}$ is the prevalence of *Plasmodium* spp. $k$ among participants in study $l$. In many

cases, $\theta_k^{(l)}$ is not equivalent to community prevalence, due to characteristics of the study

participants that are not representative of the surrounding community.

A key assumption of the latent class model is that diagnostic outcomes are conditionally

independent. That is, by assuming that the sensitivity and specificity of a given diagnostic

method is unique for each *Plasmodium* spp., the outcome that we observe for one parasite

species using a given diagnostic method is modelled as independent of the outcomes observed

for all other parasite species and diagnostic methods. This implies that the probability of a set of

diagnostic outcomes observed across all five *Plasmodium* spp. is equal to the product of the

probabilities of the diagnostic outcome for each *Plasmodium* spp. Nevertheless, the assumption

of conditional independence still allows for interactions between *Plasmodium* spp. that arise in

the context of misdiagnosis. For example, if a *P. knowlesi* infection is misdiagnosed as a *P.*

*malariae* infection using LM, then the sensitivity of LM for *P. knowlesi* and the specificity of

LM for *P. malariae* are penalized, because both a false-negative *P. knowlesi* diagnosis and a

false-positive *P. malariae* diagnosis occurred.

100 Galvin Life Sciences Center, Notre Dame, IN 46556; huber.j.h@wustl.edu

*Accounting for Differences in Study Design*

Studies identified in the systematic review varied by enrollment and diagnostic criteria. Where

enrollment in a study required a positive *Plasmodium* spp. diagnosis by LM or PCR, we

normalized the probabilities of eq. (1), such that they were consistent with the subset of possible

diagnostic outcomes that could be observed with that study design.

Because *P. knowlesi* and *P. malariae* share morphological similarities[3,6], studies may

diagnose samples as "*P. knowlesi / P. malariae*" with LM, indicating that the microscopist

identified *P. knowlesi* and/or *P. malariae* parasites in the sample but could not make a more

precise mono-infection or co-infection diagnosis. To accommodate this in our model, we defined

parameters $se_{LM}^{("Pk/Pm"|Pk,l)}$ and $se_{LM}^{("Pk/Pm"|Pm,l)}$ as the sensitivities of LM to diagnose samples in

study $l$ as "*P. knowlesi / P. malariae*", given that the samples contained *P. knowlesi* and *P.*

*malariae* parasites, respectively.

*Inference*

Using PCR as the gold standard, we fit a hierarchical latent class model of clinical diagnosis to

the studies identified in our systematic review to estimate study-level and species-level variation

in LM sensitivity and specificity for each *Plasmodium* spp. We fit our model in a Bayesian

framework using Stan by running four independent chains of 2,000 samples, each with a warm-

up period of 1,000 samples[24]. We tested for convergence with the Gelman-Rubin statistic and

pooled the independent chains for a posterior distribution of 4,000 samples. Supplementary

analyses were performed to evaluate the sensitivity of our posterior estimates to the inclusion of

each study and to the assumption of PCR as the gold standard. See the Supporting Information

for more details.

## RESULTS

**RESULTS**

Of the 176 unique studies identified using MEDLINE and Web of Science, 12 studies met the

inclusion criteria, and their data comparing LM and PCR diagnostic performance were extracted

(Fig. 1). The studies enrolled febrile patients presenting in health clinics in Malaysia (n = 7),

Thailand (n = 2), Indonesia (n = 1), Myanmar (n = 1), and China (n = 1). Among the 12,690 total

patients enrolled across the 12 studies, the pooled percentage positive by PCR was 17% for *P.*

*falciparum*, 24% for *P. vivax*, 38% for *P. knowlesi*, 1.7% for *P. malariae*, and 0.36% for *P. ovale*

(Table 1). The studies varied widely in the percentage positive by PCR across *Plasmodium* spp.,

encompassing a wide range of epidemiological settings and study designs (i.e., criteria for patient

enrollment) in which we estimated LM diagnostic performance.

*Figure 1. PRISMA Flow Diagram.* *Flow diagram of the studies identified using MEDLINE and*

*Web of Science for the systematic review.*

160 **_Table 1. Reported Plasmodium spp. percentage positive by diagnostic method._** *The percentage*

161 *of study participants positive by LM and PCR are reported for each Plasmodium spp. in each*

162 *study, along with the study location, year, and total number and type of samples collected. For*

163 *Pk and Pm LM percentage of study participants positive, * indicates that the percentage positive*

164 *was computed using a diagnosis of "Pk/Pm."*

| Ref. | Location | Samples | Type | Years | P. falciparum | | P. vivax | | P. knowlesi | | P. malariae | | P. ovale | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | PCR | LM | PCR | LM | PCR | LM | PCR | LM | PCR | LM |
| [15] | Malaysia | 960 | LM+ | 2001-2006 | 26 (249) | 23 (218) | 51 (487) | 45 (430) | 28 (266) | 0.0 (0) | 0.42 (4) | 33 (312) | 0.73 (7) | 0.21 (2) |
| [19] | Thailand | 1,874 | Any Febrile | 2006-2007 | 41 (762) | 37 (687) | 64 (1192) | 54 (1021) | 0.53 (10) | 0.0 (0) | 1.3 (24) | 0.16 (3) | 0.96 (18) | 0.0 (0) |
| [16] | Malaysia | 189 | LM+ | 2008-2011 | 37 (70) | 39 (74) | 35 (66) | 35 (67) | 22 (42) | 0.0 (0) | 1.1 (2) | 27 (51) | 0.0 (0) | 0.0 (0) |
| [11] | Malaysia | 461 | LM+ | 2009-2011 | 7.2 (33) | 12 (54) | 16 (74) | 13 (59) | 85 (392) | 92* (425) | 0.87 (4) | 2* (425) | 0.0 (0) | 0.0 (0) |
| [13] | Malaysia | 227 | Any Febrile | 2008-2010 | 42 (95) | 41 (92) | 41 (92) | 38 (87) | 16 (36) | 0.0 (0) | 0.88 (2) | 15 (33) | 0.044 (1) | 0.044 (1) |
| [21] | China | 560 | Any Febrile | 2008-2012 | 28 (159) | 28 (156) | 51 (288) | 49 (276) | 0.36 (2) | 0.0 (0) | 1.6 (9) | 0.0 (0) | 2.7 (15) | 0.0 (0) |
| [7] | Malaysia | 303 | PCR+/LM+ | 2010-2011 | 43 (130) | 47 (142) | 16 (47) | 16 (47) | 44 (132) | 42* (128) | 0.66 (2) | 42* (128) | 0.0 (0) | 0.0 (0) |
| [12] | Thailand | 297 | Any Febrile | 2012 | 9.1 (27) | 3.4 (10) | 8.8 (26) | 5.1 (15) | 0.0 (0) | 0.0 (0) | 0.34 (1) | 0.34 (1) | 0.0 (0) | 0.0 (0) |
| [20] | Malaysia | 457 | LM+ | 2012-2013 | 11 (51) | 12 (54) | 32 (144) | 30 (138) | 58 (267) | 40 (185) | 0.22 (1) | 18 (81) | 0.044 (2) | 0.022 (1) |
| [17] | Myanmar | 90 | Any Febrile | 2013-2015 | 44 (40) | 43 (39) | 20 (18) | 19 (17) | 0.0 (0) | 0.0 (0) | 1.1 (1) | 1.1 (1) | 0.0 (0) | 0.0 (0) |
| [18] | Indonesia | | Any Febrile | 2015 | | | | | | | | | | |
| | Batubara | 1,270 | | | 6.2 (79) | 3.4 (43) | 10 (131) | 6.5 (83) | 12 (148) | 0.0 (0) | 1.2 (15) | 0.0 (0) | 0.0 (0) | 0.0 (0) |
| | Langkat | 544 | | | 16 (87) | 9.6 (52) | 16 (85) | 10 (56) | 5.9 (32) | 0.0 (0) | 1.1 (6) | 0.18 (1) | 0.0 (0) | 0.0 (0) |
| | South Nias | 1,917 | | | 12 (227) | 15 (294) | 17 (321) | 6.8 (131) | 14 (263) | 0.0 (0) | 5.6 (107) | 0.0 (0) | 0.0 (0) | 0.0 (0) |

| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | Malaysia | 3,541 | PCR+/LM+ | 2015-2017 | 4.9 (173) | 4.9 (174) | 2.5 (87) | 2.5 (87) | 92 (3255) | 93* (3280) | 1.1 (40) | 93* (3280) | 0.085 (3) | 0.0 (0) |
| **Total** | | 12,690 | | | 17 (2182) | 16 (2089) | 24 (3058) | 20 (2514) | 38 (4845) | 32 (4018) | 1.7 (218) | 34 (4316) | 0.36 (46) | 0.032 (4) |

After validating on 200 simulated datasets (Fig. S1), we applied our hierarchical latent class

model to the data from the 12 studies identified in the systematic review. Our fitted hierarchical

latent class model captured the variation in the observed data (Fig. S2) and revealed differences

in LM diagnostic performance across *Plasmodium* spp. (Fig. 2). Specifically, we estimated that

the species-level mean sensitivity of LM was 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum*,

40.3% (22.0 – 61.5%) for *P. vivax*, 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 –

22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale*. Species-level mean

specificity of LM was consistently high across *Plasmodium* spp. and was estimated at 98.5%

(96.7 – 99.4%) for *P. falciparum*, 98.8% (97.3 – 99.5%) for *P. vivax*, 100% (99.9 – 100%) for *P.*

*knowlesi*, 99.3% (98.0 – 99.8%) for *P. malariae*, and 100% (100 – 100%) for *P. ovale*. These

results were robust to the assumption of PCR as the gold standard (Fig. S4).

*Figure 2. Group-level posterior estimates of LM diagnostic performance.* The group-level

distributions of LM sensitivity (A, C, E, G, I) and LM specificity (B, D, F, H, I) are shown for

*Plasmodium falciparum (teal; A, B), Plasmodium vivax (orange; C, D), Plasmodium knowlesi*

*(purple; E, F), Plasmodium malariae (pink; G, H), and Plasmodium ovale (green; I, J). Thick*

*lines are the maximum a posteriori estimates, and thin lines are 25 posterior samples.*

The variance in the hierarchical distributions of LM diagnostic performance in Fig. 2 revealed

the extent of variation across studies, a feature that depended upon both the diagnostic measure

and the *Plasmodium* spp. considered (Fig. 3). In general, for a given *Plasmodium* spp., we

estimated greater variation across studies in LM sensitivity than specificity. For example, for *P.*

*falciparum*, we estimated that logit-transformed standard deviation of LM sensitivity was 1.61

(1.26 – 2.09), suggesting that the range of sensitivities that fell within one standard deviation of

the mean was 12.5 – 78.2%. By comparison, the estimated logit-transformed standard deviation

of LM specificity for *P. falciparum* was 1.48 (1.13 – 1.93), corresponding to a range of

specificities within one standard deviation of the mean of 93.8 – 99.7%. Across *Plasmodium*

spp., study-level estimates of LM sensitivity and specificity for *P. falciparum*, *P. vivax*, and *P.*

*malariae* exhibited greater variation than for *P. knowlesi* and *P. ovale.*

**Figure 3. Site-level posterior estimates of LM diagnostic performance.** *The site-level posterior estimates of (A) LM sensitivity and (B) LM specificity are shown for P. falciparum (teal), P.*

*vivax (orange), P. knowlesi (purple), P. malariae (pink), and P. ovale (green). Circles are the*

*median posterior estimate, and the vertical segment is the 95% credible interval. The horizontal*

*line is the posterior median of the group-level mean, and the horizontal shaded region is the*

*corresponding 95% credible interval.*

Because the estimates of LM diagnostic performance varied across the unique studies, we then

assessed its relationship with observed PCR prevalence (Fig. 4). We observed strong, positive

correlations between PCR prevalence and LM sensitivity for *P. falciparum* (Pearson Correlation

Test: $\rho = 0.66$; $p = 0.01$) and *P. knowlesi* ($\rho = 0.83$; $p = 0.0015$) and weaker, positive correlations

for *P. vivax* ($\rho = 0.40$) and *P. ovale* ($\rho = 0.012$), though the latter two were not statistically

significant associations. By contrast, for *P. malariae*, there was a negative correlation between

PCR prevalence and LM sensitivity, though this estimate was also not statistically significant.

Across *Plasmodium* spp., increased PCR prevalence of *P. knowlesi* was associated with reduced

sensitivity of LM for *P. vivax* ($\rho = -0.58$; $p = 0.029$), highlighting a possible source of

misdiagnosis. Additional negative associations were observed between PCR prevalence and LM

sensitivity across *P. falciparum*, *P. knowlesi*, and *P. malariae*—*Plasmodium* spp. that are

commonly misdiagnosed—though these quantities were not statistically significant.

Generally, for a given *Plasmodium* spp., PCR prevalence was negatively associated with

LM specificity (Fig. 4B). For *P. knowlesi*, this association was strong and statistically significant

($\rho = -0.62$; $p = 0.017$), and additional weaker, yet statistically non-significant relationships were

observed for *P. falciparum*, *P. vivax*, and *P. ovale*. The opposite relationship was observed for *P.*

*malariae,* though this quantity was not statistically significant. Across *Plasmodium* spp.,

increased prevalence of *P. malariae* was associated with reduced specificities of LM for *P.*

*falciparum* (ρ = -0.79; p < 0.001) and *P. vivax* (ρ = -0.72; p = 0.0036), and increased prevalence

of *P. knowlesi* was associated with reduced specificity of LM for *P. malariae*.

**Figure 4. Correlations between Plasmodium spp. fever prevalence and LM diagnostic**

**performance.** *The correlations between Plasmodium spp. fever prevalence and (A) LM*

*sensitivity and (B) LM specificity are reported. The color represents the strength of the*

*correlation, with red colors denoting positive correlations and blue colors denoting negative*

*correlations. '*' denotes p < 0.05, '**' denotes p < 0.01, and '***' denotes p < 0.001.*

**DISCUSSION**

In this systematic review and meta-analysis, we estimated study-level and species-level variation

in the malaria diagnostic performance of light microscopy in epidemiological settings with co-

circulation of the five *Plasmodium* spp. that cause human malaria. Our analysis revealed

consistently low sensitivity of light microscopy to diagnose *Plasmodium* spp. infection.

Sensitivity of light microscopy was estimated to be considerably lower for *P. knowlesi*, *P.*

*malariae*, and *P. ovale* than for *P. falciparum* and *P. vivax*. This suggests that the burden of *P.*

*knowlesi*, *P. malariae*, and *P. ovale* in a clinical setting may be appreciably underestimated,

consistent with a recent study of *P. ovale* in health clinics in Kenya[4].

Post-hoc analyses revealed relationships between the diagnostic performance of light

microscopy and the epidemiological setting. In general, we noted a positive association between

the PCR prevalence of a *Plasmodium* spp. and the sensitivity of light microscopy for that

*Plasmodium* spp. This supports a phenomenon whereby the more a microscopist encounters

samples of a *Plasmodium* spp. infection in a clinical setting, the more likely they are to

accurately identify the *Plasmodium* spp. causing that infection. By contrast, increased PCR

prevalence of a *Plasmodium* spp. was associated with high false-positive probabilities for that

*Plasmodium* spp. This tendency to misdiagnose malaria infections as what is most commonly

encountered in that clinical setting could lead to ineffective monitoring of less commonly

encountered *Plasmodium* spp., such as *P. knowlesi*, *P. malariae*, *and P. ovale.*

The high probabilities of misdiagnosis estimated in this analysis could have important

consequences for malaria treatment and control. Specifically, we observed an association

between increased prevalence of *P. knowlesi* and reduced sensitivity of LM for *P. vivax*. This

suggests that in areas with *P. knowlesi*, infections of *P. vivax* may not be correctly diagnosed and

therefore may not receive radical cure therapy to clear hypnozoites and prevent relapse[25].

Additionally, increased prevalence of *P. malariae* was associated with reduced specificity of LM

for *P. vivax*, indicating that many *P. malariae* infections may be misdiagnosed as *P. vivax*. This

form of misdiagnosis could unnecessarily subject individuals to radical cure therapy, potentially

increasing the risk of acute hemolysis among individuals deficient of the glucose-6-phosphate

dehydrogenase enzyme[26].

Routine diagnosis of clinical malaria by light microscopy may prevent effective

monitoring of *P. knowlesi* transmission and burden. We estimated very low sensitivity of LM to

diagnose *P. knowlesi* infections, given the morphological similarities of the parasites to those of

*P. falciparum* and *P. malariae*[3,6] as well as likely delays in familiarity of *P. knowlesi* among

microscopists in the health systems. Sensitivity of LM was improved in settings that allowed for

a "*P. knowlesi/P. malariae*" diagnosis, indicating that further speciation is often not possible.

Although in practice *P. knowlesi* and *P. malariae* infections diagnosed by light microscopy are

confirmed by PCR in many settings[11], *P. knowlesi* infections misdiagnosed as *P. falciparum*, for

instance, would not be subject to confirmatory PCR. This could lead to an underestimate of *P.*

*knowlesi* burden, affecting epidemiological assessments of *P. knowlesi* infection risk.

Our analysis is subject to a number of limitations. Our systematic review may not have

identified all studies with relevant data, including those studies not indexed by MEDLINE and

Web of Science. We limited our review to studies that tested for all five *Plasmodium* spp.

However, studies that included subsets of the five *Plasmodium* spp. could still be informative of

species-level diagnostic performance. Our latent class model assumed conditional independence

of diagnosis across *Plasmodium* spp. Future extensions of this work could account for the

correlation structure of LM diagnosis across the *Plasmodium* spp., due to shared morphologies of

the parasites. Additionally, to address non-identifiability issues, we assumed PCR to be the gold

standard. Although sensitivity analyses revealed that our species-level estimates were robust to

this assumption, future work could jointly estimate the diagnostic performance of both methods,

providing a more complete characterization of misdiagnosis of *Plasmodium* spp. in settings with

co-circulation of multiple *Plasmodium* species.

**NOTES**

*Acknowledgments*

The authors thank Parker Ladwig for helpful advice on conducting a systematic review.

*Author Contributions*

J.H.H. and T.A.P. conceived of the study. J.H.H. developed the methodology and performed the

systematic review and analyses. J.H.H. and M.E. verified the underlying data. J.H.H., M.E.,

C.K., and T.A.P. interpreted the results. J.H.H. and T.A.P. wrote the initial draft, and all authors

provided comments on the final draft. All authors had access to the underlying data.

*Disclaimer*

The funding sources had no role in the study design, data collection, analysis, interpretation, or

writing of the report.

*Financial Support*

This work was supported by a Graduate Research Fellowship from the National Science

Foundation to J.H.H, a Richard and Peggy Notebaert Premier Fellowship from the University of

Notre Dame to J.H.H, the National Institute of General Medical Sciences [grant number

1R35GM143029-01] to T.A.P, and the National Institute of Allergy and Infectious Diseases

[grant number R21-AI137891] to C.K.

*Potential Conflicts of Interest*

All authors have no conflicts of interest to declare.

100 Galvin Life Sciences Center, Notre Dame, IN 46556; huber.j.h@wustl.edu

*Availability of Data and Materials*

All code and data to reproduce the analyses can be accessed at

https://github.com/johnhhuber/malaria_misdiagonsis.git.

*Co-Author Contact Information*

Margaret Elliott: Department of Biological Sciences, 100 Galvin Life Sciences Center, Notre

Dame, IN, USA 46556; melliot5@nd.edu

Cristian Koepfli: Department of Biological Sciences, 100 Galvin Life Sciences Center, Notre

Dame, IN, USA 46556; ckoepfli@nd.edu

T. Alex Perkins: Department of Biological Sciences, 100 Galvin Life Sciences Center, Notre

Dame, IN, USA 46556; taperkins@nd.edu

**REFERENCES**

1. Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, Cameron E, Twohig KA,

   Pfeffer DA, Rozier JA, Gibson HS, Rao PC, Casey D, Bertozzi-Villa A, Collins EL, et al., 2019.

   Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum, 2000–17: a

   spatial and temporal modelling study. *The Lancet 394*: 322–331

2. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E,

   Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, et al., 2019.

331     Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000–17: a spatial and

332     temporal modelling study. *The Lancet 394*: 332–343

333. Feachem RGA, Chen I, Akbari O, Bertozzi-Villa A, Bhatt S, Binka F, Boni MF, Buckee C,

334     Dieleman J, Dondorp A, Eapen A, Sekhri Feachem N, Filler S, Gething P, Gosling R, et al.,

335     2019. Malaria eradication within a generation: ambitious, achievable, and necessary. *The Lancet*

336     *394*: 1056–1112

337. Akala HM, Watson OJ, Mitei KK, Juma DW, Verity R, Ingasia LA, Opot BH, Okoth RO,

338     Chemwor GC, Juma JA, Mwakio EW, Brazeau N, Cheruiyot AC, Yeda RA, Maraka MN, et al.,

339     2021. Plasmodium interspecies interactions during a period of increasing prevalence of

340     Plasmodium ovale in symptomatic individuals seeking treatment: an observational study. *The*

341     *Lancet Microbe 2*: e141–e150

342. Whittaker C, Slater H, Nash R, Bousema T, Drakeley C, Ghani AC, Okell LC., 2021. Global

343     patterns of submicroscopic Plasmodium falciparum malaria infection: insights from a systematic

344     review and meta-analysis of population surveys. *The Lancet Microbe*: S2666524721000550

345. Singh B, Sung LK, Matusop A, Radhakrishnan A, Shamsul SS, Cox-Singh J, Thomas A,

346     Conway DJ., 2004. A large focus of naturally acquired Plasmodium knowlesi infections in

347     human beings. *The Lancet 363*: 1017–1024

348. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM., 2013. Limitations of microscopy to

349     differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum,

350     Plasmodium vivax and Plasmodium knowlesi. *Malar J 12*: 8

351. Anon., 2015. *Guidelines for the Treatment of Malaria*. 3rd ed. Geneva: World Health

352     Organization

353. Kantele A, Jokiranta TS., 2011. Review of cases with the emerging fifth human malaria parasite, Plasmodium knowlesi. *Clin Infect Dis 52*: 1356–1362

50. Blumberg S, Lloyd-Smith JO., 2013. Comparing methods for estimating R0 from the size distribution of subcritical transmission chains. *Epidemics 5*: 131–145

51. Barber BE, William T, Dhararaj P, Anderios F, Grigg MJ, Yeo TW, Anstey NM., 2012. Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. *Malar J 11*: 401

52. Baum E, Sattabongkot J, Sirichaisinthop J, Kiattibutr K, Jain A, Taghavian O, Lee M-C, Huw Davies D, Cui L, Felgner PL, Yan G., 2016. Common asymptomatic and submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular and serological studies: a challenge to malaria elimination. *Malar J 15*: 333

53. Chua KH, Lim SC, Ng CC, Lee PC, Lim YAL, Lau TP, Chai HC., 2015. Development of High Resolution Melting Analysis for the Diagnosis of Human Malaria. *Scientific Reports 5*: 15671

54. Cooper DJ, Rajahram GS, William T, Jelip J, Mohammad R, Benedict J, Alaza DA, Malacova E, Yeo TW, Grigg MJ, Anstey NM, Barber BE., 2020. Plasmodium knowlesi Malaria in Sabah, Malaysia, 2015-2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only Plasmodium Species. *Clin Infect Dis 70*: 361–367

55. Cox-Singh J, Davis TME, Lee K-S, Shamsul SSG, Matusop A, Ratnam S, Rahman HA, Conway DJ, Singh B., 2008. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. *Clin Infect Dis 46*: 165–171

56. Goh XT, Lim YAL, Vythilingam I, Chew CH, Lee PC, Ngui R, Tan TC, Yap NJ, Nissapatorn V, Chua KH., 2013. Increased detection of Plasmodium knowlesi in Sandakan division, Sabah as revealed by PlasmoNex™. *Malar J 12*: 264

367. Han TZ, Han KT, Aye KH, Hlaing T, Thant KZ, Vythilingam I., 2017. Comparison of microscopy and PCR for the detection of human Plasmodium species and Plasmodium knowlesi in southern Myanmar. *Asian Pacific Journal of Tropical Biomedicine 7*: 680–685

368. Lubis IND, Wijaya H, Lubis M, Lubis CP, Divis PCS, Beshir KB, Sutherland CJ., 2017. Contribution of Plasmodium knowlesi to Multispecies Human Malaria Infections in North Sumatera, Indonesia. *J Infect Dis 215*: 1148–1155

369. Putaporntip C, Hongsrimuang T, Seethamchai S, Kobasa T, Limkittikul K, Cui L, Jongwutiwes S., 2009. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. *J Infect Dis 199*: 1143–1150

370. Yusof R, Lau YL, Mahmud R, Fong MY, Jelip J, Ngian HU, Mustakim S, Hussin HM, Marzuki N, Mohd Ali M., 2014. High proportion of knowlesi malaria in recent malaria cases in Malaysia. *Malar J 13*: 168

371. Zhou X, Huang J-L, Njuabe MT, Li S-G, Chen J-H, Zhou X-N., 2014. A molecular survey of febrile cases in malaria-endemic areas along China-Myanmar border in Yunnan province, People's Republic of China. *Parasite 21*: 27

372. Rahim MAFA, Munajat MB, Idris ZM., 2020. Malaria distribution and performance of malaria diagnostic methods in Malaysia (1980-2019): a systematic review. *Malar J 19*: 395

373. Gonçalves L, Subtil A, de Oliveira MR, do Rosário V, Lee P-W, Shaio M-F., 2012. Bayesian Latent Class Models in Malaria Diagnosis. *PLoS ONE 7*: e40633

374. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, Brubaker M, Guo J, Li P, Riddell A., 2017. *Stan* : A Probabilistic Programming Language. *J Stat Soft 76*

395. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA., 2009.

Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. *The*

*Lancet Infectious Diseases 9*: 555–566

396. Baird JK, Battle KE, Howes RE., 2018. Primaquine ineligibility in anti-relapse therapy of

Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6

polymorphisms. *Malar J 17*: 42, s12936-018-2190-z